A study published in the Journal of the American Medical Association reported that carriers of the CYP2C19 loss-of-function allele face higher risks of cardiovascular death, myocardial infarction, and stroke, particularly for in-stent thrombosis events (12). This evidence concerns the gene CYP2C19 and myocardial infarction.